Clinical Trial: Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07369492) titled 'Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma' on Jan. 18.

Brief Summary: The purpose of this study is to evaluate the safety and tolerability of BAFF-R CAR-T Cells in Adult Subjects with CD19-Negative relapsed or refractory B-Cell Lymphoma.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: CD19 Negative Relapsed/Refractory B-Cell Lymphoma

Intervention: BIOLOGICAL: BAFF-R CAR-T cells

BAFF-R CAR-T cells, single intravenous infusion

Recruitment Status: RECRUITING

Sponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

Disclaimer: Curat...